Federal regulators have approved the first treatment designed to change the course of Sanfilippo syndrome type A, a rare inherited disease that slowly strips young children of speech, thinking, and movement. The U.S. Food and Drug Administration approved Fayuvi (rebisufligene etisparvovec-hopf) on Sept. 17, a one-time intravenous gene therapy for pediatric patients with mucopolysaccharidosis type IIIA. Until that decision, care was limited to managing symptoms.
For the small number of American families living with this diagnosis, the approval turns an abstract hope into a series of concrete, urgent decisions. Parents now have to ask which hospitals will administer the infusion, whether their insurer will cover it, and whether their child still meets the criteria on the label, which limits treatment to children with preserved neurodevelopmental function.
That last point carries real weight. Sanfilippo syndrome type A moves quickly, and the approved indication does not cover children whose neurological decline is already advanced. Timing, not just eligibility, will shape who benefits.
A Single Infusion, and a Narrow Window for Treatment
Sanfilippo syndrome type A is caused by a deficiency of the sulfamidase enzyme, which the body needs to break down a sugar molecule called heparan sulfate. Without it, that molecule builds up in cells and damages the central nervous system. Ultragenyx, which brought the therapy through approval, estimates the disease affects about 3,000 to 5,000 patients in commercially accessible geographies, with a median life expectancy of 15 years.
Fayuvi uses a modified, non-infectious adeno-associated virus serotype 9 to deliver a working copy of the SGSH gene into a patient's cells, so the body can produce the missing enzyme itself. It is given once, through a vein, in a health care setting equipped to manage infusion reactions.
Karim Mikhail, director of the FDA's Center for Biologics Evaluation and Research, called the decision "a meaningful step forward" for these children and for the promise of gene therapy in rare disease.
The therapy carries a demanding support regimen. Every patient receives corticosteroids beginning one day before the infusion and continuing for a minimum of eight weeks afterward, which means a treatment plan measured in months, not a single hospital visit.
Inside the Trial Data Behind the Approval
The FDA granted standard full approval, not accelerated approval, based on an open-label, single-arm, multicenter study. Because the disease is so rare, there was no placebo group. Instead, treated children were compared with an untreated group drawn from natural history data.
Ultragenyx reported that 17 treated patients in the modified intention-to-treat group were compared with 27 untreated patients from an external natural history cohort. Researchers measured the mean change in Bayley-III cognitive raw scores between ages 24 and 60 months, a stretch when untreated children typically plateau and then decline. Treated patients scored 23.5 points higher than the natural history group. Cerebrospinal fluid heparan sulfate levels fell across all age groups, and follow-up now extends to nearly eight years.
Kevin M. Flanigan, director of the Center for Gene Therapy at Nationwide Children's Hospital in Columbus and principal investigator on the study, said the therapy addresses "a pressing unmet clinical need" and offers families a promising option.
The design has real limits. A single-arm study with an external comparison group cannot rule out every source of bias, and 17 treated patients is a small evidence base by the standards of common diseases. That trade-off is typical for ultra-rare conditions, where a randomized trial may not be feasible or ethical.
Cost, Coverage, and the Wait for Treatment Centers
Ultragenyx did not publish a price in its approval announcement. Market coverage of the decision published the same dayreported that the company set the U.S. per-patient wholesale acquisition cost at $3.95 million. Wholesale acquisition cost is a list price, not what an insurer actually pays.
The company says commercial product is expected to ship to Qualified Treatment Centers within 30 to 60 days. Those centers are U.S. health care institutions with specialized gene therapy expertise and training, and the network has not yet been published. Ultragenyx says details will appear on a product website in the coming days. Families outside major metro areas should expect travel, since gene therapy centers cluster around large academic hospitals.
Ultragenyx says its UltraCare program will assign trained gene therapy guides to help families understand insurance coverage and navigate treatment, reachable at 888-756-8657. The therapy is manufactured in the United States, at the company's facility in Bedford, Massachusetts, and at Andelyn Biosciences in Columbus, Ohio.
Safety Monitoring Families Should Expect
The most common side effects reported in at least 5% of patients were elevated liver enzymes, vomiting, abnormal behavior, diarrhea, fever, low white cell counts, Cushingoid features from steroid treatment, reduced appetite, low platelets and anemia. Liver enzyme elevation was reported in 85% of patients.
Labeling also carries warnings for thrombotic microangiopathy, a serious clotting condition reported with other AAV gene therapies, though no cases occurred in the Fayuvi studies. The label additionally warns about hypersensitivity and infusion reactions. Because the vector's genetic material could integrate into the genome, there is a long-term potential risk of malignancy, which is why patients are followed for years.
Practically, that means blood draws. Platelet counts are checked weekly for the first four weeks and monthly for six months. Liver function is monitored until two weeks after the steroid taper is complete. Vaccines are avoided for 30 days before treatment and during steroid therapy, and caregivers are advised on hand hygiene around bodily fluids and waste for three months because of temporary vector shedding.
None of this replaces a conversation with a pediatric metabolic specialist. Parents who think their child may qualify should ask their child's neurologist or geneticist about referral to a treatment center, and should not stop any current medication without clinical guidance.
Fayuvi received orphan drug, fast track and breakthrough therapy designations during development. The FDA declined to approve an earlier version of the application in 2025 over manufacturing issues rather than clinical data, and the company resubmitted this year. Side effects can be reported through the FDA's MedWatch program.
Key Questions Answered
What did the FDA approve?
Fayuvi (rebisufligene etisparvovec-hopf), a one-time intravenous gene therapy for pediatric patients with mucopolysaccharidosis type IIIA, also called Sanfilippo syndrome type A. It is the first approved treatment for the disease.
Which children are eligible?
The label covers pediatric patients with neurologic manifestations of MPS IIIA who still have preserved neurodevelopmental function. A metabolic specialist determines whether an individual child qualifies.
When will it actually be available?
Ultragenyx expects to ship commercial product to Qualified Treatment Centers within 30 to 60 days. The list of participating centers has not yet been published.
How much will it cost families?
Ultragenyx did not publish a price in its approval materials, but market coverage reported a U.S. wholesale acquisition cost of $3.95 million per patient. Out-of-pocket costs depend on insurance, and the company's UltraCare program offers coverage navigation support.
What are the main safety concerns?
Elevated liver enzymes, vomiting, fever, low platelet and white cell counts, and steroid-related effects were most common. Labeling warns about thrombotic microangiopathy, infusion reactions and a long-term potential malignancy risk.
Does this cure Sanfilippo syndrome type A?
No. The trial showed treated children maintained or improved cognitive scores compared with untreated children over the study period. It did not show a cure, and long-term outcomes are still being followed.
